IZ Express

Issue 1765: July 10, 2024

Top Stories
Immunize.org Website and Clinical Resources 
Featured Resources
Notable Publications
Upcoming Events

Top Stories

CDC posts updated standing orders for adult mpox vaccination
CDC issued Standing Orders for Administering JYNNEOS (Mpox) Vaccine by Subcutaneous Injection to Persons 18 Years of Age and Older. This document replaces CDC’s older standing orders templates that predated ACIP’s October 2023 interim recommendations for routine use of mpox vaccine in adults at risk of exposure to mpox. It addresses subcutaneous administration of the 2-dose Jynneos (Bavarian Nordic) vaccine series. It does not address the alternative intradermal route that was authorized when Jynneos was in short supply, but which is not now routinely recommended. 

View the standing orders for Jynneos mpox vaccination of at-risk adults

Related Links 

CDC’s “COVID-19 Can Surge throughout the Year” web page shows why year-round vaccine protection is needed

Many have hoped that COVID-19, after its initial pandemic phase, would quickly settle into a winter epidemic pattern, with predictably minimal activity at other times of year, much like influenza or RSV disease. That is not the case. On July 3, CDC published COVID-19 Can Surge throughout the Year, a web page that explains the current understanding of COVID-19 epidemiology, highlighting the year-round threat of epidemic COVID-19 disease. A portion of the summary from the web page is reprinted below.

Since the start of the COVID-19 pandemic, infections with SARS-CoV-2, the virus that causes COVID-19, have peaked during the winter and also surged at other times of the year. These periodic surges are due in part to the emergence of new variants and decreasing immunity from previous infections and vaccinations. Because the evolution of new variants remains unpredictable, SARS-CoV-2 is not a typical “winter” respiratory virus. . . .

CDC continues to monitor seasonal trends of COVID-19 and the factors driving these trends, including the emergence of new variants, and to collaborate with state and local health departments, commercial laboratories, and global partners. On June 27, the Advisory Committee on Immunization Practices (ACIP), an independent advisory group to CDC, recommended that persons ≥6 months of age receive the 2024–2025 COVID-19 vaccines when they become available this fall. 

Related Links 

Review your COVID-19 resources with the latest version of Immunize.org’s “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools”

Immunize.org reviews its Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools at least monthly, prominently indicating when it was last revised at the top of the page. The CDC Director officially accepted the June 2024 ACIP vote to recommend routine use of 2024–2025 COVID-19 vaccines in people age 6 months and older as approved or authorized by FDA. The checklist indicates CDC’s plan to update its clinical guidance for the 2024–2025 Formula COVID-19 vaccines once they become available in late August or September. Clinical guidance for the 2023–2024 Formula COVID-19 vaccines is unchanged.

The updated checklist also provides the most recent web link to “Communication and Print Resources.”

Refer to the checklist for links to important information about the COVID-19 Bridge Access Program, which ends in August. The 2024–2025 Formula COVID-19 vaccines will be available at no cost through the VFC program for eligible children through age 18; however, there will be no federal program to provide them at no cost to uninsured adults.  

All COVID-19 vaccine providers should review this checklist regularly. Download the latest documents and discard any outdated versions. The checklist is posted on Immunize.org's Vaccines A–Z: COVID-19 main page to help practices stay up to date.

Related Links

“How Is RSV Preventive Antibody Different from an RSV Vaccine?” Watch the 3-minute answer, part of the Ask the Experts Video Series on YouTube. 

This week, our featured episode from the Ask the Experts Video Series answers the question, How Is RSV Preventive Antibody Different from an RSV Vaccine? RSV vaccines are not given to babies. The product given to infants and toddlers to protect them from RSV disease is not a vaccine, but a monoclonal antibody product that provides immediate protection from RSV that lasts at least 5 months. The video briefly contrasts active immunization from vaccines and passive immunization from nirsevimab (Beyfortus, Sanofi).

The 3-minute video is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions.

Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.

Related Link 
Vaccines in the news

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.

Immunize.org Website and Clinical Resources
Spotlight on the website: Explore new features that make it even easier to use our video library

This week in the Spotlight, we highlight recent enhancements to our video library page, which is located under the “Clinical Resources” tab of the menu and at www.immunize.org/clinical/video. Enhancements include:

  • Faster page loading: Video library pages now load quickly. Simply click on a thumbnail image to open a new window and play the video.
  • Filters for search results: Filter by vaccine or disease name or pick one of four video subject filters: Ask the Experts, Improving the Vaccination Experience, Partner Videos, and Website Introduction (Orientation Video Series). Selecting a filter refreshes the page, limiting results to videos that match your selection. You may choose a second filter after results from the first are displayed. 
  • Sort by date options: Select the “Sort by” dropdown on the right of page. Then select whether you want to see results with the newest or oldest videos first.

Whether you need something specific or are just browsing, we hope you enjoy using these new features to access our wealth of educational video content. 

Recap: Immunize.org updates its patient handout, “You're 16 ... We Recommend These Vaccines for You!”

Immunize.org and the Society for Adolescent Health and Medicine (SAHM) recently updated their patient handout, You're 16 ... We Recommend These Vaccines for You! The handout now includes COVID-19 as a routinely recommended vaccine and a footnote was added to indicate that RSV vaccine may be recommended during pregnancy. Vaccines normally administered to preteens (but which may be needed by teens who are not up to date) are now grouped in a separate table.

Related Link

  • Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria

Summary: Immunize.org updated these clinical resources in May and June

IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org clinical resources are free to distribute. 

Web Pages

New! Translations: All Clinical Resources and VISs

Immunize.org Materials for Clinicians 

Immunize.org Materials for Patients  Related Links 
  • Immunize.org: Clinical Resources A–Z main page to see educational materials sorted by category 
  • Immunize.org: Ask the Experts main page to access more than 1,300 questions answered by Immunize.org experts 
  • Immunize.org: Translations main page to quickly find all languages available for VISs and Clinical Resources

Featured Resources

Voices for Vaccines offers free online course on handling conversations about vaccine hesitancy and establishing trust, even if you are not a healthcare professional

Voices for Vaccines (VFV) is offering Becoming Trusted Messengers, a free online course intended for anyone, including people who are not healthcare professionals, interested in supporting vaccine confidence in their community. This course offers an easy, evidence-based method of handling vaccine hesitancy online or in person.

Participants will learn how to:

  • Build trust authentically
  • Assess what is really causing concern
  • Get buy-in to reconsider vaccine fears
  • Start and keep an open line of communication
  • Build vaccine confidence in your personal network

Enroll in the course.

NACCHO releases 2023 Immunization Profile Study, identifying insufficient staffing, interjurisdictional data sharing, and vaccine hesitancy as major barriers

The National Association of County and City Health Officials (NACCHO) released its 2023 Immunization Profile Study, assessing immunization capacity at local health departments (LHD) nationwide. The report provides insight into the status of immunization programs at the local level, characterizes their activities to control vaccine-preventable diseases and provide immunization services, and identifies challenges and opportunities to strengthen LHD immunization programs. 

View the report.

Follow us and share Immunize.org posts featuring Ask the Experts questions and our clinical resources on Facebook, Instagram, and LinkedIn!

Immunize.org launched a social media program to highlight our educational resources for a new audience of vaccinators. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators. Please view and share our newest feature, the Ask the Experts Video Series.


Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:

Mighty handy! Immunize.org offers adult and lifetime handheld immunization record cards you can provide your patients. 

Immunize.org's personal immunization record cards, printed on rip-proof, smudge-proof, water-proof paper, are designed to last a lifetime. They fit in a wallet when folded. The record cards are for you to give to your patients as a permanent personal vaccination record and are sold in boxes of 250.

Make bulk purchases and receive quantity discounts. For quotes on larger quantities or customizing, or to request sample cards, call 651-647-9009 or email admininfo@immunize.org.

Related Links

Make bulk purchases and receive quantity discounts. For quotes on larger quantities or customizing, or to request sample cards, call 651-647-9009 or email admininfo@immunize.org.

Related Links

Notable Publications

"National and State-Specific Estimates of Settings Where Adults Received Influenza, Updated COVID-19, and RSV Vaccinations, 2023–2024 Respiratory Virus Season, United States" published by CDC

On June 10, CDC published National and State-Specific Estimates of Settings Where Adults Received Influenza, Updated COVID-19, and RSV Vaccinations, 2023–2024 Respiratory Virus Season, United States on its website. The study highlights the value of convenient access to vaccines in pharmacies, while also stressing the ongoing importance for many adults of vaccination in their doctor’s office. The conclusion section appears below. 

This study demonstrated that large proportions of adults received their flu, updated COVID-19, and RSV vaccination at pharmacies or drug stores. Pharmacies or drug stores provide extended access, and convenience for adults to receive annual routine vaccination and can be an effective source for vaccination during a pandemic. However, medical offices remain a vital place of vaccination, especially given the demonstrated benefit of healthcare provider recommendations in increasing vaccine uptake. Moreover, in a separate survey, adults reported that a doctor’s office was their most preferred place to receive a vaccination, followed by a pharmacy or store. In order to improve adult vaccination coverage, it will be important that medical offices continue to stock and recommend vaccination, especially those that serve rural and lower income adults and racial and ethnic minorities.

“Megastudy Shows That Reminders Boost Vaccination but Adding Free Rides Does Not” published in Nature

In its June 26 issue, Nature published Megastudy Shows That Reminders Boost Vaccination but Adding Free Rides Does Not. A portion of the abstract appears below. 

Here we show that offering people free round-trip Lyft rides to pharmacies has no benefit over and above sending them behaviourally informed text messages reminding them to get vaccinated. We determined this by running a megastudy with millions of CVS Pharmacy patients in the United States testing the effects of (1) free round-trip Lyft rides to CVS Pharmacies for vaccination appointments and (2) seven different sets of behaviourally informed vaccine reminder messages. Our results suggest that offering previously vaccinated individuals free rides to vaccination sites is not a good investment in the United States, contrary to the high expectations of both expert and lay forecasters. Instead, people in the United States should be sent behaviourally informed COVID-19 vaccination reminders, which increased the 30-day COVID-19 booster uptake by 21% (1.05 percentage points) and spilled over to increase 30-day influenza vaccinations by 8% (0.34 percentage points) in our megastudy. More rigorous testing of interventions to promote vaccination is needed to ensure that evidence-based solutions are deployed widely and that ineffective but intuitively appealing tools are discontinued.

Upcoming Events

Virtual: CDC hosts COCA call, “Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers,” on July 16 at 2:00 p.m. (ET); CE credit offered

CDC will host a Clinician Outreach and Communication Activity (COCA) call titled Update on Highly Pathogenic Avian Influenza A(H5N1) Virus for Clinicians and Healthcare Centers, 2:00–3:00 p.m. (ET) on July 16. During this COCA call, presenters will discuss the epidemiology and clinical features of human cases of HPAI A(H5N1) virus infection; describe the risk of human infection with HPAI A(H5N1) viruses, identify higher-risk populations, and what to assess in clinical settings; and will describe testing, using antivirals, and infection prevention and control recommendations for patients with HPAI A(H5N1) virus infection.

A recording of the presentation will be archived for viewing on the COCA call web page a few hours after the live event ends.

Free continuing education credit (CME, CPE, CNE, and other) will be offered for this COCA call. Registration is not required.

Link for the July 16 call.

For more upcoming events, visit our Calendar of Events.

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .